A new journey comes after a new time. On the last day of 2021, the results of the "Golden Quality" Award for listed companies in 2021 were officially announced by Shanghai Securities News. Based on the comprehensive evaluation of the listed company's performance data, profitability, financial status, industry position, market share and other factors, Hybribio was awarded the "Golden Quality" Sustainable Growth Award in 2021 based on its solid performance growth and strong upward development momentum.

No matter how turbulent the internal and external environment is, Hybribio insists on working on the molecular diagnostic testing field, and develops steadily by keeping close to its main business, and forms an in vitro diagnostic industry chain system integrating nucleic acid testing reagents and fully automated instruments, providing more accurate and standardized support for the national medical diagnostic service network with strong R&D strength, perfect technical system and stable marketing network. The tenacity of development and strong growth momentum will encourage Hybribioers to keep going in 2022!

Expansion and growth

Hybribio holds a leading position in HPV testing for early screening of cervical cancer, and is a leader in maternal and child health and birth defect prevention and control. The company has further extended its industrial chain in recent years and focused on expanding its third-party medical laboratory testing business.

At present, Hybribio Group has 29 medical laboratories in full operation. Medical laboratories in Beijing, Xian, Changsha, Guiyang, Chengdu, Wuhan, Nanchang and Chongqing are being upgraded and constructed to increase the nationwide coverage of third-party medical testing business and achieve large-scale development. Hybribio has gradually established a nationwide third-party medical testing service network, featuring molecular genetics, tumor genetic testing and mass spectrometry, and serving advanced molecular diagnostic technology to primary medical institutions nationwide.

With the product line, sales network and customer resources accumulated for many years in nucleic acid testing products, Hybribio has long expanded and extended the upstream and downstream of the industry. In the dilemma of "broken chain" in the global industry, Hybribio has further improved its production capacity, expanded its overall output by six times and increased its production capacity by ten times, showing a large-scale growth; worked hard on raw materials and solved key problems through "key technology" With nucleic acid testing products and testing services complementing each other, we have built an integrated business model of "reagents + instruments + medical testing services"

This year, Hybribio continues to innovate and develop, vigorously laying out new technology platforms such as mass spectrometry assay, digital PCR assay, high-throughput sequencing and POCT, and making efforts toward infection, genetic disease, rare disease, nutritional assessment, endocrine and drug concentration detection. We have also established joint research platforms with several universities, cultivated multi-dimensional talents, and accelerated the development of industry-university-research integration through university-enterprise cooperation.

Growing along the way & being well recognized

Since its establishment, Hybribio has focused on nucleic acid detection and insisted on independent innovation. The key technology patent "HPV Genotyping Diagnostic Kits and Gene Chip Preparation Method" was awarded the 18th Chinese Patent Gold Award. The company has been awarded the "little giant" enterprise, national technology innovation demonstration enterprises and other major national innovation honors. It has set up Guangdong Province Human Papilloma Virus (HPV)-related disease molecular diagnosis engineering technology research and development center, Guangdong Province provincial enterprise technology center, postdoctoral research workstation, doctoral research workstation and other R & D innovation platforms.

In 2021, Hybribio enjoyed a reputation in the capital and consumer markets, and its business maintained continuous growth. The company had been awarded the "Top 50 Value Listed Companies in China GEM", "China Listed Company Investor Tianma Award", "Most Growing Listed Company in Biomedicine" and other major awards, and Mr. K. C. Kun, the founder and president of Hybribio, was awarded the title of "Best CEO of Listed Company"......

These special honors witnessed Hybribio's efforts in 2021, highlighted the enterprise's development strength and value prospect, and drew a successful conclusion for 2021. Looking forward to 2022, Hybribio will continue to adhere to the development strategies of "Three Hybribio", "Nucleic Acid 99, 999" and "Hybribio B53". We will insist on independent innovation, continuously improve our independent innovation ability and core competitiveness, and insist on conscientious quality and scientific management. By promoting the integrated business model of "nucleic acid testing products + medical testing services", we will make the most of the synergistic effect of the upstream and downstream industry chains, drive the endogenous growth of the whole industry chain model, and continue to write the Hybribio story in the new year with excellent business performance.